Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients — EOLoa

Loiasis Clinical Trial

Official title:
Randomized Clinical Trial, Double-blind, Single-dose Drug and Escalating Infection Intensities, Evaluating the Safety and Efficacy of Moxidectin 2 mg, Ivermectin-controlled, in Loa Loa Microfilaremic Patients

Status Active, not recruiting

Clinical Trial Summary

This study aims at evaluating the safety and efficacy of Moxidectin 2 mg in patients with low intensities of microfilariae of Loa loa.

Clinical Trial Description

This clinical trial will be randomized, double blind, and will compare Moxidectin to ivermectin. This study will be conducted in Cameroon. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04049851
Study type	Interventional
Source	Center for Research on Filariasis and Other Tropical Diseases, Cameroon
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 7, 2022
Completion date	August 14, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02644525` - Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa	Phase 2
Not yet recruiting	`NCT04035174` - Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa	N/A
Completed	`NCT05085665` - Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events	Phase 4
Active, not recruiting	`NCT04258670` - Spontaneous Antigenemia in Loiasis
Completed	`NCT04049630` - Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients	Phase 2
Not yet recruiting	`NCT06350851` - Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination	N/A
Completed	`NCT01111305` - Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis	Phase 2
Not yet recruiting	`NCT06252961` - A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects	Phase 2/Phase 3